Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK

INTRODUCTION: Antivirals, such as molnupiravir, and SARS-CoV-2 neutralising monoclonal antibodies (nMAbs), such as sotrovimab, reduced the risk of hospitalisation and death in clinical trials of high-risk non-hospitalised patients with Covid-19. However, the real-world benefits of these drugs are un...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodwin, Amanda T., Thompson, Jonathan S., Hall, Ian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016683/
https://www.ncbi.nlm.nih.gov/pubmed/36920896
http://dx.doi.org/10.1371/journal.pone.0281915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016683/
https://www.ncbi.nlm.nih.gov/pubmed/36920896
http://dx.doi.org/10.1371/journal.pone.0281915

Ejemplares similares